Absci (NASDAQ:ABSI) used a presentation at the Leerink Partners Global Healthcare Conference to outline how the company is applying its internal AI-driven drug design platform to generate ...
Drug discovery is like molecular Tetris. Chemists snap atoms together, adjusting the pieces until everything fits, and ...
In 2025, we were very pleased to report tremendous progress across all pillars of the company. First of all, in business development, we were delighted with the progress in our collaboration with MSD ...
AI has designed candidate drugs for antibiotic-resistant infections and genetic diseases. But efforts to incorporate AI into the design of lipid nanoparticles (LNPs), the revolutionary delivery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results